Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?

Clinical colorectal cancer - 1 Dec 2011

Inno Alessandro, Di Salvatore Mariantonietta, Cenci Tonia, Martini Maurizio, Orlandi Armando, Strippoli Antonia, Ferrara Anna Maria, Bagalà Cinzia, Cassano Alessandra, Larocca Luigi Maria, Barone Carlo

Abstract excerpt

BACKGROUND: The KRAS mutation is not responsible for all cases of resistance to anti-epidermal growth factor receptors (EGFRs) in metastatic colorectal cancer (mCRC), and new predictive and prognostic factors are actively being sought. PATIENTS AND METHODS: We retrospectively evaluated the efficacy of a cetuximab-containing treatment in 73 patients with mCRC according to KRAS and BRAF mutational status as well as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunoenzyme Techniques

Share to Neoplasm Metastasis

Share to Proto-Oncogene Proteins c-met

Share to PTEN Phosphohydrolase

Share to ras Proteins

Share to Receptor, IGF Type 1

Source

Identifiers

PMID: 21729677
DOI: 10.1016/j.clcc.2011.03.028

Genes

KRAS
MET
BRAF
PTEN
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer?PMID 21729677Read ↗

Impact of cetuximab in current treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.Semantic proximity Read ↗

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer.Semantic proximity Read ↗

Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.Semantic proximity Read ↗

Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer.Semantic proximity Read ↗

Lack of Relationship Between Clinical Features and KRAS Mutations in Patients with Metastatic Colorectal Cancer.Semantic proximity Read ↗

KRAS mutations and sensitivity to anti-EGFR monoclonal antibodies in metastatic colorectal carcinoma: an open issue.Semantic proximity Read ↗

KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis.Semantic proximity Read ↗

Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.Semantic proximity Read ↗

Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers.Semantic proximity Read ↗

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patientsSemantic proximity Read ↗

Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.